Peter Attia· MD
If you prevented SARC from binding to middle T, the transforming ability of middle T was eliminated.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
If you prevented SARC from binding to middle T, the transforming ability of middle T was eliminated.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
We'd also found that Sark phosphorylated a site in polyamimidal T, a tyrosine site that was highly phosphorylated. And even more importantly, that if you mutated that tyrosine residue to phenylalanine, polyamimidal T completely lost its ability to transform cells.